Actelion advances clinical development of its specialty immunology pipeline compounds (Actelion Ltd)

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 April 2015 - Actelion Ltd (SIX: ATLN) announced today that it is accelerating its clinical development efforts in the field of immunological disorders, following a broad scientific, medical and commercial evaluation of a series of its selective S1P1 receptor modulators, discovered in-house. Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis, with patient enrollment expected imminently. In parallel, Actelion will also initiate a Phase II study with ponesimod in patients suffering from chronic graft versus host disease. In addition, a second selective...